V. Parfenov

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

M. Zaaroor, U. Bogdahn, K. Schlingensiepen, 2010, Neuro-oncology.

Results of a phase Iib active-controlled study with AP 12009 for patients with recurrent or refractory anaplastic astrocytoma

U. Bogdahn, K. Schlingensiepen, A. Mahapatra, 2008 .

Randomized, active-controlled phase IIb study with trabedersen (AP 12009) in recurrent or refractory high-grade glioma patients: Basis for phase III endpoints.

U. Bogdahn, K. Schlingensiepen, A. Mahapatra, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted therapy with AP 12009 in recurrent or refractory glioblastoma patients: Results of a phase Iib study

U. Bogdahn, K. Schlingensiepen, A. Mahapatra, 2008 .

Results of a phase IIb study in recurrent or refractory glioblastoma patients with the TGF-beta-2 inhibitor AP 12009

U. Bogdahn, K. Schlingensiepen, A. Mahapatra, 2007 .